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Abstract
Introduction: Tuberous sclerosis complex (TSC) is a genetic disease resulting from mutation in TSC1 or TSC2 and
subsequent hyperactivation of mammalian Target of Rapamycin (mTOR). Common TSC features include brain
lesions, such as cortical tubers and subependymal giant cell astrocytomas (SEGAs). However, the current treatment
with mTOR inhibitors has critical limitations. We aimed to identify new targets for TSC pharmacotherapy.
Results: The results of our shRNA screen point to glutamate-cysteine ligase catalytic subunit (GCLC), a key enzyme
in glutathione synthesis, as a contributor to TSC-related phenotype. GCLC inhibition increased cellular stress and
reduced mTOR hyperactivity in TSC2-depleted neurons and SEGA-derived cells. Moreover, patients’ brain tubers
showed elevated GCLC and stress markers expression. Finally, GCLC inhibition led to growth arrest and death of
SEGA-derived cells.
Conclusions: We describe GCLC as a part of redox adaptation in TSC, needed for overgrowth and survival of
mutant cells, and provide a potential novel target for SEGA treatment.
Keywords: Tuberous Sclerosis Complex, Glutamate-cysteine ligase, Cellular stress, Brain tumors, Cell death
Introduction
Tuberous sclerosis complex (TSC) is a common neuro-
cutaneous disease, inherited in an autosomal dominant
pattern, affecting 1:6,000 live births [29]. It is caused by
mutations in either of two genes encoding components
of the TSC protein complex: TSC1 (hamartin) and TSC2
(tuberin). Disrupted TSC complex function results in
overactivation of mammalian Target of Rapamycin com-
plex 1 (mTORC1), an important regulator of cell metabol-
ism [26]. mTORC1 overactivation is believed to be the
main cause of the pathological overgrowth of cells and
development of tubers in different tissues, including
the brain. Patients develop 3 types of brain lesions:
subependymal nodules, cortical tubers and subependy-
mal giant cell astrocytomas (SEGAs) of glio-neuronal
origin [4, 27]. The last two contribute to TSC clinical
symptoms—cortical tubers are considered as epilepto-
genic [18], while growth of SEGA is commonly associ-
ated with the development of hydrocephalus and can
lead to severe complications, including death [30]. Ex-
tensive research concerning tuberous sclerosis com-
plex has led to a breakthrough in the treatment of this
disease, enabling pharmacotherapy with mTOR inhibi-
tors [20, 30]. mTOR inhibitors reportedly decrease
SEGA size, and everolimus was recently approved by
the FDA and EMA for TSC-associated SEGAs [34].
Moreover, many reports indicate that mTOR inhib-
ition may alleviate epilepsy severity in TSC patients
[21, 44]. However, withdrawal of mTOR inhibitor is
associated with rapid tumor regrowth, and mTOR in-
hibitors use is burdened with significant adverse
events, including infections, mouth ulcers, and hyper-
lipidemia [38]. In some cases, use of mTOR inhibitors
can even lead to life-threatening complications, including
sepsis and death [41]. Thus, the development of a more
efficient and safer drug is of utmost importance.
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Therefore, in this study, we aimed to provide new po-
tential drug targets in TSC pharmacotherapy by identi-
fying proteins crucial for the pathological overgrowth
typical of TSC. We report results of an shRNA screen, in
which we silenced expression of genes potentially linked
to TSC pathology or mTOR signaling. We identified sev-
eral proteins that possibly contribute to TSC-related
phenotype. Among them, we focus on the role of
glutamate-cysteine ligase catalytic subunit (GCLC), a pro-
tein important for the control of oxidative stress levels.
We show that GCLC inhibition increases cellular stress
and reduces mTOR hyperactivity in TSC2-depleted neu-
rons and SEGA-derived cells. Moreover, we provide evi-
dence that this protein might be a potential target in the
pharmacotherapy of TSC.
Materials and methods
Drugs and antibodies
All drugs and antibodies used for the study are described in
Supplementary materials and methods (Additional file 1).
DNA constructs
pCx EGFP-N1, pSuper and β-actin-GFP [19] plasmids
have been described previously [2, 3, 19]. The sequences
encoding shRNAs used in the screen were cloned into
the pSuper vector and are listed in Additional file 2:
Table S1. mRNA sequences targeted in TSC2 and GCLC
as well as cloning strategy for TSC2 and its shRNA-
resistant mutants is described in Supplementary mate-
rials and methods (Additional file 1).
Neuronal cultures, transfection, drug treatments, and
immunofluorescence
The animals used to obtain neurons for tissue cultures were
sacrificed according to the protocols approved by the First
Ethical Committee in Warsaw, Poland (permission #75/
2010), which are in compliance with the European Com-
munity Council Directive (86/609/EEC). Primary cortical
cultures were prepared from embryonic day 19 (E19) rat
brains as described previously [25]. For the purpose of
immunofluorescence and morphometric analysis, neu-
rons were transfected on Day 6 in vitro (DIV6) with Li-
pofectamine2000 as described earlier [35]. Twenty
nanomolar rapamycin or 10 μM L-BSO were added to
the medium 2 h after transfection and the medium was
not changed until the end of the experiment. Neurons
were fixed with 4 % paraformaldehyde (PFA) and 4 %
sucrose in PBS at DIV10. Immunofluorescent staining
was performed as described recently [25].
When a highly efficient gene transfer was required
(Western blot), plasmids were introduced to freshly iso-
lated neurons (DIV0) using the AMAXA nucleofection
procedure (Lonza, Basel, Switzerland) as described re-
cently [25]. For GCLC inhibition in nucleofected cells,
10 μM L-BSO was added to the medium 18 h post
nucleofection. Neurons were lysed 30 h later.
SEGA-derived cell culture and treatment
The study was approved by The Ethics Board at the
Children’s Memorial Health Institute, Warsaw, Poland.
The samples of patients’ SEGAs were analyzed after writ-
ten consent was obtained from their parents. Patients
were diagnosed as having TSC according to Roach’s
criteria. The patients presented with acute hydroceph-
alus and were operated after large SEGAs were re-
vealed in brain MRI (Additional file 3: Figure S3a).
Freshly resected SEGA samples from two patients
were cut into small pieces and trypsynized for 1 h at
37 °C. After trypsinization the tissue fragments were
dispersed with a pipette to small clumps or single
cells. The obtained cell suspension was centrifuged
and the pellet was suspended in DMEM 4.5 g/l glucose
supplemented with 5 % fetal bovine serum (FBS; Gibco,
Karlsruhe, Germany) and antibiotics (100 U/ml penicillin,
100 μg/ml streptomycin; Sigma, St. Louis, MO). Cells
were maintained for about 2 weeks until they reached
confluence and were used for experiments.
For live imaging experiments, cells were plated on
gelatin-coated μ-Slide VI 0.4 plates (Ibidi, Planegg,
Germany). During pharmacological treatment, the medium
was changed every second day and the drugs were
used as follows: U0126 (20 μM), rapamycin (20 nM),
L-BSO (20 or 100 μM).
COS-7 cell culture and transfection
COS-7 cells (ATCC) were cultured in DMEM supple-
mented with 10 % FBS and antibiotics. Cells were trans-
fected using Lipofectamine2000 (Invitrogen, Carlsbad,
CA) according to manufacturer protocol.
shRNA library screen
Target genes covered by the shRNA library are listed in
Supplementary materials and methods (Additional file 1).
The majority of targets was selected based on published
data [5, 6, 45]; for more detailed description see Sup-
plementary materials and methods (Additional file 1).
Whenever possible, 3 shRNAs were designed against
given mRNA and shRNAs coding sequences and cloned
into the pSuper vector. However, in some cases, only two
shRNAs could be designed.
In screening experiments, cortical neurons were trans-
fected on Day 6 in vitro (DIV6) with TSC2sh together
with pools of pSuper plasmids that encoded shRNAs
targeting a given gene and β-actin-GFP. Each culture
plate contained 3 control variants: (i) transfected with
pSuper/β-actin-GFP, (ii) transfected with TSC2sh/pSuper/
β-actin-GFP, and (iii) transfected with TSC2sh/pSuper/β-
actin-GFP and treated with 20 nM rapamycin. Four days
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after transfection, the neurons were fixed and cell images
were acquired. To avoid variability caused by differences
between cultures, the area of neuron soma was quantified
as a percentage of the mean value obtained for neurons in
pSuper/β-actin-GFP control variant from the same experi-
mental plate. Two independent screening experiments
were performed, and the mean value was calculated from
both of them for each shRNA pool.
In vivo electroporation in neonates
All the procedures were approved by the First Ethical
Committee in Warsaw, Poland (permission #569/2014),
which is in compliance with the European Community
Council Directive (86/609/EEC). Neonates (P0; Wistar,
both sexes) were anesthetized by hypothermia and the
plasmid solution was injected to the right lateral ven-
tricle. Next, the animals were subjected to electrical
pulses. Electroporated animals were warmed on a heat-
ing pad for several minutes before being returned to the
mother. For detailed electroporation protocol, rat tissue
preparation and staining procedures see Supplementary
materials and methods (Additional file 1).
Human tissue samples
The cases included in this study were obtained from the
archives of the departments of neuropathology of the
Academic Medical Center (University of Amsterdam)
and the University Medical Center in Utrecht (UMCU).
We examined 10 surgical specimens, 5 cortical tubers
(male/female: 3/2; mean age at surgery: 16.8 years, range:
10–23), and 5 subependymal giant-cell astrocytomas
(SEGA; male/female: 3/2; mean age at surgery: 12 years,
range: 1–23) from patients undergoing epilepsy surgery
or surgery for obstructive hydrocephalus. Informed con-
sent was obtained for the use of brain tissue and for ac-
cess to medical records for research purposes. Tissue
was obtained and used in a manner compliant with the
Declaration of Helsinki. For the SEGA, we used the
WHO classification of tumors of the central nervous
system [24]. All patients fulfilled the diagnostic criteria
for TSC [11]. All patients included had TSC2 mutations.
Normal-appearing control cortex was obtained at aut-
opsy from 5 age-matched patients without history of sei-
zures or other neurological diseases. Autopsied brain
tissues from patients with Alzheimer’s disease (AD) and
trauma (as well as skin specimens) were also examined
(as positive controls for immunohistochemical analysis;
AD and trauma specimens (for HO-1 and Hsp70) and
skin specimens (for GCLC)). All autopsies were performed
within 24 h after death. Histologically normal temporal
neocortex (without evidence of significant neuronal loss,
gliosis, or malformation) from two patients undergoing ex-
tensive surgical resection of the mesial structures for the
treatment of medically intractable complex partial epilepsy
was also used for immunocytochemical analysis. For hu-
man tissue preparation and staining procedures, see Sup-
plementary materials and methods (Additional file 1).
Image analysis and quantification
Olympus Cell^R station was used to obtain neuron im-
ages in screening experiments and for live imaging of
SEGA-derived cells. Confocal images of immunofluores-
cently stained cortical neurons and rat brain sections
were obtained with a Zeiss LSM710NLO microscope.
The morphometric analysis of neuron soma area and
immunofluorescence intensity analysis were performed
via MetaMorph image analysis software (Universal Im-
aging Corporation, Downingtown, PA) with Integrated
Morphometry Analysis and Region Measurements func-
tions, respectively. For the analysis of SEGA-derived
cells’ area, ImageJ software was used. For 3D reconstruc-
tion and morphometric analysis of GFP positive cells
from rat brain slices, Imaris software (Bitplane, Zurich,
Switzerland) was used.
Statistical analysis
The data concerning neurons were obtained from three
batches of cells, with the exception of the screening ex-
periment that was performed on two batches of neurons.
SEGA live imaging was performed twice for each of two
independent SEGA-derived cultures. For animal studies,
we reduced the number of animals to the minimum re-
quired for reliable statistics. Animals were randomly
allocated to experimental groups and no blinding was
done. The specimens were coded for microscopy analysis.
The statistical analyses were performed using Prism Soft-
ware (GraphPad, San Diego, CA) and Kruskal-Wallis test
followed by Dunn’s post hoc test, or two-way ANOVA de-
pending on the type of data analyzed. In the latter case
variance was similar between compared groups. The num-
ber of values (analyzed cells) and animals in experimental
groups is provided in Supplementary materials and
methods (Additional file 1).
Results
Screening experiments reveal new proteins indispensable
for abnormal growth of TSC2-depleted neurons
One characteristic feature of TSC is the presence of en-
larged dysmorphic neurons and giant cells in cortical tu-
bers [13]. This aberrant cell size increase is thought to
be due to loss of either TSC1 or TSC2 and mTORC1
overactivation [12, 39]. To enable screening for the
genes and proteins required for the mTORC1-
dependent cell size increase, we first modeled aberrant
neuronal growth in vitro. Utilizing plasmid-based
shRNA expression [3], we efficiently depleted cultured
rat cortical neurons of TSC2 (Additional file 3: Figure S1a)
using either one of two shRNAs (TSC2sh#1, TSC2sh#2).
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When introduced to neurons at Day 6 in vitro (DIV6),
these shRNAs effectively increased (i) levels of ribosomal
S6 protein phosphorylated at Ser235/236 (P-S6) and (ii)
neuronal soma size (Fig. 1a). Both observations are
consistent with the data from TSC patients [36], TSC-
model mouse brain tissue [12, 43], and in vitro TSC
models [28, 39]. Importantly, both the increase in P-S6
levels and cell soma size were blocked by treatment with
Fig. 1 GCLC knockdown reverses the phenotype of model dysmorphic neurons. a TSC2 knockdown in rat cortical neurons as a model of TSC-related
dysmorphic neurons. Neurons were transfected with empty pSuper vector, TSC2sh#1, or sh#2 together with GFP. Next, neurons were treated with 20
nM rapamycin or DMSO (control), fixed, and immunostained for P-S6. Representative images, results of analysis of P-S6 intensity, and neuron soma area.
Scale bar: 25 μm. Plots represent mean +/−SEM. **p < 0.01, ***p < 0.001 in Kruskal-Wallis with Dunn’s post-hoc test. Sample sizes for experimental
groups are provided in Supplementary materials and methods (Additional file 1). For additional results of TSC2sh validation, see Additional file 3:
Figure S1. b Results of analysis of neuronal soma area from screening experiments. Each point represents mean +/− SEM obtained from two independent
experiments. For more details see Additional file 2: Table S1 and Additional file 3: Table S2. c Western blot analysis of GCLC level in rat cortical neurons
4 days after nucleofection with empty pSuper vector, GCLCsh-mix used in the screening experiments or individual GCLCsh#1, sh#2, and sh#3.
α-tubulin is shown as a loading control. d Representative images of rat cortical neurons after TSC2 knockdown with use of 2 different shRNAs
and simultaneous GCLC knockdown with use of mixed shRNAs (as in the screen) or 2 individual shRNAs. GFP-encoding plasmid was co-transfected for
visualization of modified neurons. Scale bar: 50 μm. e Neuronal soma area of rat cortical neurons after TSC2 and GCLC knockdown. Plot represents
mean +/−SEM. ns- not significant, *p < 0.05, **p < 0.01, ***p < 0.001 in Kruskal-Wallis with Dunn’s post-hoc test. Sample sizes for experimental groups
are provided in Supplementary materials and methods (Additional file 1)
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an mTOR inhibitor (20 nM rapamycin) (Fig. 1a). The
specificity of both TSC2sh was confirmed by “rescue” ex-
periments, in which neuronal overgrowth was prevented
by co-transfecting neurons with TSC2sh and a plasmid
encoding TSC2 mRNA resistant to shRNA (Additional
file 3: Figure S1b and S1c).
Having validated our in vitro model of mTOR-
dependent neuronal hypertrophy, we performed screen-
ing experiments to identify genes and proteins necessary
for the aberrant cell size increase. To this end, we used a
library of shRNAs designed to target mRNAs encoding
147 proteins linked to mTOR signaling pathway or TSC
pathology in past studies (see Supplementary materials
and methods (Additional file 1) for detailed library de-
scription and the list of targeted genes and Additional
file 2: Table S1 for shRNAs sequences). shRNAs target-
ing given mRNA were transfected to cortical neurons as
pools to ensure effective knockdown. The pools of
shRNAs were co-transfected to DIV6 neurons with
TSC2sh#1 and plasmid encoding GFP, for visualization
of transfected cell morphology. As a control, we used
neurons transfected with (i) empty pSuper, (ii) pSuper
and TSC2sh#1, and (iii) pSuper and TSC2sh#1, treated
with 20 nM rapamycin. Analysis of the cell somas of
transfected neurons 4 days post transfection revealed
that the majority of tested shRNAs had no effect on
TSC2sh#1-induced hypertrophy. However, 30 shRNA
pools caused a significant decrease in the neuronal soma
area of TSC2-depleted cells (Additional file 3: Figure S1b
and Table S2). Twenty-three of these genes were con-
firmed in follow-up experiments using TSC2sh#2 instead
of TSC2#sh1 (Additional file 3: Table S2).
TSC-related neuronal hypertrophy depends on GCLC
We subsequently decided to focus on GCLC, a first rate
limiting enzyme of glutathione synthesis that was previ-
ously identified in a yeast study as potentially linked to
TOR signaling [5]. GCLC plays a crucial role in protect-
ing cells from oxidative stress and damage caused by re-
active oxygen species (ROS). There is also evidence
indicating increased cellular stress and ROS levels in
TSC pathology [28].
To verify the results of screening experiments, we
tested the specificity of GCLC shRNAs and its pheno-
typic effects. Indeed, all three GCLCsh individually and
as a pool efficiently reduced levels of GCLC in nucleo-
fected cortical neurons cultured in vitro (Fig. 1c). We
next tested effects of single shRNAs on the phenotype of
the model hypertrophic neurons and confirmed that
both GCLCsh#1 and GCLCsh#3, similar to the GCLCsh
pool, reversed the hypertrophic phenotype induced by
TSC2 depletion with either TSC2sh#1 or TSC2sh#2
(Fig. 1d and 1e). GCLCsh#2 appeared to have non-
specific toxic effects when transfected to DIV6 neurons,
and therefore was not studied further.
We next examined whether GCLC is important for
the hypertrophy of TSC2-depleted neurons in vivo. For
this purpose, we performed in vivo electroporation of
shRNAs encoding plasmids into proliferating neuronal
precursors in the subventricular zone (SVZ) of newly
born rodents (Fig. 2a), as described previously [8, 22].
Six days after electroporation, the TSC2sh#2-electropo-
rated neuroprogenitors in the rostral migratory stream
had a significantly higher volume when compared to the
cells of control rats (Fig. 2b-2d). Consistent with our
Fig. 2 GCLCsh blocks aberrant growth in TSC in vivo model. a Scheme of in vivo electroporation. b Representative images of cells in rostral
migratory stream obtained in in vivo experiments. Newborn rats were electroporated with pSuper vector or TSC2sh#2 together with pSuper or
GCLCsh#1. Plasmid encoding GFP was used to visualize modified cells. Scale bar: 50 μm. c Exemplary 3D reconstructions of GFP-positive cells in
rostral migratory stream. Scale bar: 3 μm. d Quantification of cell soma volume of cells migrating in the rostral migratory stream. Plot represents
mean +/−SEM. ***p < 0.001 in Kruskal-Wallis with Dunn’s post-hoc test. Sample sizes for experimental groups are provided in Supplementary
materials and methods (Additional file 1)
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observations from cultured neurons, co-electroporation
of GCLCsh with TSC2sh blocked the size increase of
TSC2-deficient cells.
Furthermore, we verified the importance of GCLC for
aberrant growth of TSC2-defficient neurons using a spe-
cific inhibitor of GCLC catalytic activity, L-Buthionine-
sulfoximine (L-BSO) [14]. Neuronal soma enlargement
was fully blocked by the addition of L-BSO (10 μM) to
the cultured neurons transfected with TSC2sh (either #1
or #2), supporting our finding that GCLC is necessary
for TSC-related aberrant growth (Fig. 3a).
GCLC inhibition increases cellular stress and reduces
mTOR activation in TSC2-depleted neurons
Previous work showed that knocking out or down TSC2
elevates cellular stress [28, 32] and eventually leads to
apoptotic death in neurons [28]. Yet, TSC-lacking brain
cells survive in both mouse models and TSC patients’
brain lesions, suggesting their adaptation to such stress.
We thus hypothesized that if GCLC contributes to this
adaptation, blocking its activity in TSC2-deficient cells
should perturb the redox balance. Consistent with previ-
ous findings, TSC2 knockdown neurons showed higher
levels of oxidative stress markers—heme oxygenase 1
(HO-1) and heat shock protein 70 (Hsp70)—compared
to control cells (Fig. 3b). Importantly, inhibiting GCLC
activity with L-BSO further increased HO-1 and Hsp70
in TSC2-deficient cells but did not lead to visible induc-
tion of those markers in control neurons (Fig. 3b). We
also note that GCLC level is higher in TSC2-depleted
cells and, in contrast to control cells, cannot be further
increased upon L-BSO treatment (Fig. 3b). As GCLC
mitigates oxidative stress, its elevated expression is likely
an adaptive response to an increase in ROS in TSC2
knockdown neurons. Inhibition of GCLC seems to dis-
turb this adaptation, increases cellular stress, and pre-
vents aberrant cell size increase. Importantly, GCLC
inhibition decreases mTORC1 activity reflected by P-S6
levels in TSC2-depleted neurons but not in control
cells (Fig. 3b), which could explain the inhibition of
aberrant growth.
TSC patients’ brain lesions show increased levels of stress
markers and GCLC
Assuming that GCLC-dependent oxidative stress adapta-
tion is necessary to develop TSC-related cellular hyper-
trophy, we should observe increased stress markers and
GCLC also in cortical tubers in patients’ tissue. To test
this, we immunostained brain sections from individuals
affected with TSC for HO-1 and Hsp70 as well as for
GCLC (Fig. 4, see also Additional file 3: Figure S2 for
additional controls). Consistent with the conclusions
from published data [28] and our in vitro studies, we ob-
served the presence of those proteins in dysmorphic
neurons and the giant cells of cortical tubers, but not in
Fig. 3 GCLC inhibitor L-BSO blocks aberrant growth, induces stress response and inhibits mTORC1 in TSC2 depleted neurons. a Representative
images and neuron soma area of TSC2-depleted and control neurons treated with 10 μM L-BSO. Scale bar: 50 μm. Plot represents mean
+/−SEM. ns- not significant, **p < 0.01, ***p < 0.001 in Kruskal-Wallis with Dunn’s post-hoc test. Sample sizes for experimental groups are provided in
Supplementary materials and methods (Additional file 1). b Western blot analysis of HO-1, Hsp70, GCLC and mTORC1 activity marker, P-S6, levels in
TSC2-depleted and control neurons after L-BSO treatment. α-tubulin is shown as a loading control
Malik et al. Acta Neuropathologica Communications  (2015) 3:48 Page 6 of 13
control brain tissue from individuals not affected with
TSC, nor in surrounding normal-appearing cells (Fig. 4).
Intriguingly, similar results were obtained for enlarged
SEGA cells as compared to control brain tissue (Fig. 4),
suggesting that the hypertrophy of cells in different types
of brain TSC lesions may depend on GCLC.
GCLC inhibition affects SEGA-derived cells growth,
proliferation, and survival
Since SEGAs are constantly growing lesions that often
require surgical resection or treatment with mTORC1
inhibitors, we examined the effects of GCLC inhibition on
the growth of cultured SEGA cells derived at the time of
surgical resection from two TSC patients (Additional file 3:
Figure S3a). To circumvent the heterogeneity of the cells
observed in these cultures, we used live imaging of SEGA-
derived cells during treatment with L-BSO (Fig. 5). This ap-
proach enabled reliable quantification of cell size increase
in comparison to initial cell area and allowed us to exclude
from analysis cells that divided or died over this time.
L-BSO added to the culture media, at either 20 or
100 μM, significantly slowed down the growth of two
SEGA-derived lines (Fig. 5a). A similar effect, although
less potent than that of a higher L-BSO dose, was obtained
upon rapamycin or rapamycin/U0126 (extracellular signal-
regulated kinase inhibitor) treatment, as described previ-
ously, on cultured SEGA-derived cells [42]. On the other
hand, lower dose of L-BSO combined with rapamycin
slowed down growth of tested cells similar to the
100 μM L-BSO (Fig 5a).
Of note, L-BSO treatment in both cell lines also in-
duced expression of cellular stress markers Hsp70 and
HO-1, as well as Nrf2, a transcription factor coordinating
expression of several oxidative stress-inducible genes, in-
cluding HO-1 [16]. Moreover, as in case of TSC2-depleted
neurons, L-BSO treatment lead to decrease in P-S6 levels
(Fig. 5b; see also Additional file 3: Figure S4 for WB re-
sults quantification). It should be noted however, that Ser
235/236 S6 phosphorylation could also decrease due to a
drop in extracellular-signal-regulated kinases (ERKs) activ-
ity in response to L-BSO. Therefore, we checked levels of
P-ERK1/2 (Thr 202/Tyr 204) in L-BSO-treated cells and
could not detect any changes over time (Additional file 3:
Figure S5). In contrast, we noticed a reduced phosphoryl-
ation of Thr 389 of p70S6K, a direct mTORC1 target
(Additional file 3: Figure S5). This supports our initial
Fig. 4 Patients’ brain lesions show markers of oxidative stress and GCLC expression. Representative images of immunohistochemical staining of Heme
oxygenase 1 (HO-1), Heat shock protein 70 (Hsp70), glutamate-cysteine ligase catalytic subunit (GCLC) in control brain sections (gray and white matter)
and TSC patients’ brain sections (cortical tubers and SEGAs). Arrows point to dysmorphic neurons, giant cells, and enlarged SEGA cells. Cell nuclei are
stained with hematoxylin. Insets show higher magnification. Scale bar: 80 μm. For additional controls, see Additional file 3: Figure S2
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Fig. 5 (See legend on next page.)
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conclusion that L-BSO gradually decreases mTORC1 ac-
tivity in SEGA-derived cells. We hypothesized that the ob-
served mTORC1 inhibition is an effect of ROS-induced
DNA damage. Indeed, supporting such mechanism,
SEGA-derived cells treated with L-BSO show progressive
increase in p53 phosphorylation (P-p53, Ser15), which is a
hallmark of DNA damage response [37] (Fig. 5b; see also
Additional file 3: Figure S4 for WB results quantification).
We also observed parallel increase in inhibitory phosphor-
ylation of Raptor (P-Raptor, Ser792), a key component of
mTORC1 (Fig. 5b; see also Additional file 3: Figure S4 for
WB results quantification). P-p53 has been shown to acti-
vate AMPK [7, 10], which in turn phosphorylates Raptor
and inhibits mTORC1 [15].
It is well established that genotoxic stress may affect cell
proliferation and survival. To address this issue, we exam-
ined the effects of longer periods of L-BSO treatment on
SEGA-derived cell fates. For this purpose, we performed
live imaging for a total of 8 days. For quantification, we di-
vided cells present at day 1 into 3 classes: cells that finally
gave rise to one cell by Day 8 (in most cases neither di-
vided nor died; class A), cells that gave rise to two or more
cells (in most cases divided at least once; class B), and
those that died (class C) (Fig. 6a, see also Additional file 3:
Figure S3b and S3c for a more detailed description of clas-
ses). In response to prolonged L-BSO treatment, the two
SEGA-derived cell lines both showed marked reduction in
cell division, and increased numbers of cells were lost.
These effects were more dramatic compared to treatment
with either rapamycin alone or combined with U0126
(Fig. 6b). However, 20 μM L-BSO-rapamycin combined
treatment gave effects comparable to higher L-BSO dose
(Fig. 6b). Moreover, L-BSO treatment induced cleavage
of Poly(ADP-ribose) polymerase 1 (PARP-1; Fig. 6c),
confirming SEGA-derived cells death.
In conclusion, we propose that mechanisms under-
lying L-BSO effects on TSC cells involve induction of
redox imbalance, oxidative DNA damage and subse-
quent increase in P-p53. These events lead consequently
to growth arrest due to AMPK-P-Raptor-dependent in-
hibition of mTORC1 and genotoxic cell death.
Discussion
Our data clearly established the requirement of GCLC
for the development of TSC-related phenotype. Findings
from in vitro and in vivo models, as well as study of
SEGA-derived cell growth, point to GCLC inhibition as
a potential strategy in TSC treatment. Moreover, we ob-
served substantial induction of cellular stress markers
and GCLC in TSC patients’ brain tubers, which supports
the clinical relevance of our findings.
The primary finding of our study is that GCLC contrib-
utes to the hypertrophy and survival of TSC2-deficient
cells. We describe increased cellular stress marker ex-
pression and mTORC1 inhibition upon L-BSO treat-
ment, both in case of TSC2 neuronal knockdown and
SEGA-derived cells. Mechanisms of this inhibition most
likely involve genotoxic stress-dependent p53 phos-
phorylation and subsequent inactivation of mTORC1
due to AMPK-dependent phosphorylation of Raptor.
Importantly, mTORC1 inhibition upon L-BSO treat-
ment was observed exclusively in TSC2-deficient cells,
which may have important clinical implications.
Our data suggest that GCLC provides protection
against elevated ROS level in TSC2-deficient cells. Redox
adaptation has also been described for various cancer
cells [40]. The signatures of this phenomenon include
induction of ROS scavenging enzymes expression and
increased sensitivity to the depletion of glutathione. In a
similar vein, it has been demonstrated that expression of
Hif1α, known to be a part of antioxidant defense in re-
sponse to ROS, is highly elevated in TSC1-deficient cells
[9, 33]. Herein, we provide evidence for increased GCLC
levels, suggesting that this ROS scavenging systems is
also upregulated. Targeting redox homeostasis or in-
creasing cellular stress is considered a supplemental
therapy for many cancers [40]. Previously, increasing ER
stress proved efficient in boosting selective cell death in
TSC-deficient cells, and was therefore suggested as a po-
tential therapy [28, 32]. In this paper, we demonstrate
that another approach, namely, targeting the synthesis of
ROS scavengers, is effective in preventing cellular hyper-
trophy as well as inducing the loss of cells with dis-
turbed TSC, likely due to mTORC1 inhibition and
genotoxic DNA damage, respectively. Of note, unlike ER
stress inductor tunicamycin, L-BSO has some synergistic
effects with rapamycin, which might be beneficial for
TSC pharmacotherapy. Our observations are also in line
with recent work from Blenis lab, showing that com-
bined ER stress induction and glutathione depletion
(See figure on previous page.)
Fig. 5 GCLC inhibition blocks growth of SEGA-derived cells and causes cellular stress, and mTORC1 inhibition. a Representative images (left) and results
of cell surface area analysis (right) of SEGA-derived cells imaged 3 times during a 5 day-treatment. SEGA#1 and SEGA#2-derived cells were
treated with 20 nM rapamycin, 20 nM rapamycin with 20 μM U0126 or 20 μM L-BSO, and 20 or 100 μM L-BSO. Scale bar: 100 μm. The plots
represent mean +/− SEM from two independent experiments. ***p < 0.001 in two-way ANOVA compared to control treated with DMSO.
Sample sizes for experimental groups are provided in Supplementary materials and methods (Additional file 1). b Western blot analysis of
stress markers (Hsp70, HO-1), Nrf2, mTORC1 activity marker P-S6, genotoxic stress marker P-p53 and P-Raptor in SEGA-derived cells lysed after
a 1-, 3- or 5-day treatment with 20 or 100 μM L-BSO. α-tubulin is shown as a loading control
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Fig. 6 GCLC inhibition causes death of SEGA-derived cells. a Schematic representation of SEGA-derived cell classes after an 8-day
treatment. b Percentage of cells classified to class A, B, or C after treatment with 20 nM rapamycin, 20 nM rapamycin with 20 μM U0126
or 20 μM L-BSO, and 20 or 100 μM L-BSO. SEGA#1 and SEGA#2-derived cells were imaged 4 times during the treatment. Next, the fate
of each cell was followed and classes were assigned. Sample sizes for experimental groups are provided in Supplementary materials and
methods (Additional file 1). For additional information, see also Additional file 3: Figure S3. c Western blot analysis of PARP (full length
and cleaved, upper and lower band, respectively) in SEGA-derived cells lysed after a 1-, 3- or 5-day treatment with 20 or 100 μM L-BSO.
α-tubulin is shown as a loading control. d Proposed model of GCLC contribution to TSC-related tumors development
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leads to death of TSC2 knockout fibroblasts cultured
in vitro and regression of TSC2-deficient xenograft tumors
development [23]. This finding strongly corroborates
our conclusion that inhibition of GCLC can be con-
sidered as a new, strategy for treatment of different
types of TSC-related tumors. Moreover synergistic ef-
fects of GCLC inhibition with rapamycin treatment
would allow combined therapy.
Our results thus suggest that GCLC inhibition could
be a novel strategy in the pharmacotherapy of TSC-
related brain tubers. However, the consequences of sys-
temic GCLC inhibition remain underinvestigated. For
example, BSO toxicity was shown in rats [17]. Never-
theless, BSO was tested in phase I clinical trial for treat-
ment of refractory malignancies with the conclusion
that it could be safely administered to patients [1].
Therefore, in our opinion, this line of research is prom-
ising, since currently available pharmacotherapy of
TSC-related brain tubers, based on mTOR inhibitors,
has important limitations. Although certainly beneficial
for patients, the treatment does not cause persistent
eradication of SEGA tubers and therefore needs to be
continued for longer periods of time [31]. In addition,
although in our study rapamycin treatment reduces
SEGA-derived cell growth, it does not lead to cell loss.
On the contrary, L-BSO alone or at lower doses in
combination with rapamycin (not shown) caused
SEGA-derived cell death. If the same results are ob-
tained in patient treatment, pharmacotherapy could
perhaps be shortened, which would be a great advan-
tage over mTOR inhibitors, known to severely impair
vital cellular processes also in healthy cells. In sum-
mary, we identified GCLC as an important player in
TSC-related hypertrophy and a potential target for the
future pharmacotherapy of SEGA.
Conclusions
In this study, we aimed to provide new potential drug
targets in TSC pharmacotherapy by identifying proteins
crucial for the pathological overgrowth typical of TSC.
Consequently, using in vitro and in vivo rodent models,
as well as SEGA-derived cells cultured in vitro we
describe GCLC as a part of redox adaptation in TSC,
needed for overgrowth and survival of mutant cells.
Inhibition of GCLC with L-BSO was able to prevent
TSC related cell hypertrophy and induce mutant cell
death, suggesting GCLC inhibition as a potential strategy
in TSC treatment. We propose that mechanisms underlying
effects of L-BSO on TSC cells involve induction of redox
imbalance, oxidative DNA damage and subsequent in-
crease in P-p53. These events lead consequently to growth
arrest due to AMPK-P-Raptor-dependent inhibition of
mTORC1 and genotoxic cell death.
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